- Home
- KALU vs AUPH Comparison
KALU vs AUPH Comparison
Compare KALU & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- AUPH
- Stock Information
- Founded
- KALU 1946
- AUPH 1993
- Country
- KALU United States
- AUPH Canada
- Employees
- KALU N/A
- AUPH N/A
- Industry
- KALU Metal Fabrications
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- AUPH Health Care
- Exchange
- KALU Nasdaq
- AUPH Nasdaq
- Market Cap
- KALU 1.1B
- AUPH 1.1B
- IPO Year
- KALU 1991
- AUPH 1999
- Fundamental
- Price
- KALU $59.79
- AUPH $8.19
- Analyst Decision
- KALU Buy
- AUPH Strong Buy
- Analyst Count
- KALU 2
- AUPH 2
- Target Price
- KALU $90.00
- AUPH $11.50
- AVG Volume (30 Days)
- KALU 129.1K
- AUPH 1.3M
- Earning Date
- KALU 04-23-2025
- AUPH 05-01-2025
- Dividend Yield
- KALU 5.19%
- AUPH N/A
- EPS Growth
- KALU N/A
- AUPH N/A
- EPS
- KALU 2.87
- AUPH 0.04
- Revenue
- KALU $3,024,000,000.00
- AUPH $235,133,000.00
- Revenue This Year
- KALU $10.02
- AUPH $11.86
- Revenue Next Year
- KALU $8.00
- AUPH $24.96
- P/E Ratio
- KALU $20.69
- AUPH $204.13
- Revenue Growth
- KALU N/A
- AUPH 33.97
- 52 Week Low
- KALU $58.75
- AUPH $4.71
- 52 Week High
- KALU $102.42
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- KALU 28.40
- AUPH 48.74
- Support Level
- KALU $58.84
- AUPH $7.93
- Resistance Level
- KALU $68.80
- AUPH $8.73
- Average True Range (ATR)
- KALU 2.12
- AUPH 0.23
- MACD
- KALU -0.87
- AUPH -0.04
- Stochastic Oscillator
- KALU 8.04
- AUPH 32.50
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.